1:Neoadjuvant therapy

Preoperative prediction of very early recurrence (within 6 months) following resection for intrahepatic cholangiocarcinoma and development of personalized neoadjuvant therapy

Efficacy and safety of RC48 combined with sintilimab and SOX neoadjuvant therapy of large volume Borrmann III, Borrmann IV, and Bulky lymph nodes expressing HER2 in locally advanced gastric/gastroesophageal junction adenocarcinoma: a multicenter, open label, single arm exploratory study